Sputnik.az reports that the effectiveness of the Sputnik V coronavirus vaccine, developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, is 91.6%.
Sputnik.az compared Sputnik V with other vaccines, noting that AstraZeneca was effective at 62.1%, Sinopharm at 79.3%, and Sinovac at 50.4%.
The website made a similar claim in another article published a few hours apart on the same day. That article said that the supply of the Sputnik V vaccine could bring Russia and the European Union closer together.
Fakt Yoxla examined whether the claim of Sputnik.az about Sinovac was true.
Vaccination against the COVID-19 virus began in Azerbaijan on January 18.
At a briefing held by the Operational Headquarters under the Cabinet of Ministers on January 16, Teymur Musayev, head of the Health Ministry's department, said that 4 million doses of vaccine had been ordered from Sinovac, of which 2 million doses had already been delivered to the country.
Since the government has so far preferred Sinovac company in importing vaccines, Fakt Yoxla has limited the study to a claim against this company.
According to Covid19.trackvaccines.org, a website that studies coronavirus vaccines, as well as The New York Times, the Sinovac vaccine has so far been approved by 20 countries.
The vaccine has been officially registered in Turkey, China, Indonesia, Chile, Brazil, Hong Kong, and the Philippines. However, only a few of these countries - Brazil, Turkey, Indonesia, and Chile - have commented on its effectiveness.
According to information published by Sinovac company on April 3, the effectiveness of the vaccine against symptomatic COVID-19 was 50.65% in Brazil and 91.25% in Turkey.
Euronews reported in March that according to a study by Hacettepe University, the effectiveness of the vaccine in Turkey was 83.5%.
As for Indonesia, the National Agency of Drug and Food Control (BPOM) said the vaccine was 65.3% effective against the disease after clinical trials.
Chile said the Sinovac vaccine was 56.5% effective. This figure is the result of a study by the University of Chile.
Thus, the effectiveness of the vaccine produced by Sinovac varies between 50.65% and 83.5%. According to Reuters, this difference is due to the trial size, patient criteria, target groups, etc.
Fakt Yoxla concludes that the claim of Sputnik.az about Sinovac is a Manipulation of Facts.
